All Comparisons
Tirzepatide vs Retatrutide
Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.
Tirzepatide: ARetatrutide: B
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Metabolic / Triple Agonist |
| Evidence Rating | A — FDA Approved | B — Phase III / NDA Filed |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Phase 3 clinical trials (Eli Lilly TRIUMPH program) |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases satiety ... | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). This triple synergy combines reduced cal... |
| Half-Life | ~5 days (116 hours) | ~6 days (allows once-weekly dosing) |
| Bioavailability | ~80% SC | SC injection |
| Molecular Weight | ~4813.5 g/mol | — |
| WADA Status | Not Prohibited | Not Prohibited |
| Dosing | 2.5–15 mg/week, titrated every 4 weeks, Once weekly (Subcutaneous) | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3, Once weekly (Subcutaneous (clinical trial formulation only)) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | FDA-approved: Mounjaro (T2D, adults and children 10+) and Zepbound (obesity/overweight with comorbidities, severe OSA including new sleep apnea approval). Compounding fully prohibited for 503B facilities. Prescription only. | Not FDA-approved. Phase 3 TRIUMPH program ongoing (Eli Lilly). TRIUMPH-4 reported 28.7% body weight loss at 12 mg over 68 weeks. Seven Phase 3 readouts expected in 2026. Regulatory submission expected 2026; approval anticipated 2027-2028. |
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.